Trial Profile
A retrospective study to evaluate long term safety and efficacy of Natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Nov 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 20 Nov 2016 New trial record